Clinical trial NCT00535691: Tacrolimus Ointment Pharmacokinetics in Infants With Atopic Dermatitis
Official title: A Randomised, Multi-centre, Double-blind, Pharmacokinetic Study of Tacrolimus Ointment (0.03%) in Paediatric Patients (Aged 3 Months to 24 Months) With Atopic Dermatitis Following First and Repeated Once Daily or Twice Daily Application of the Tacrolimus Ointment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Dermatitis, Atopic
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2007-09-26
Enrollment: 53
Sex: ALL
Minimum age (years): 3
Maximum age (years): 24
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to estimate the systemic exposure to tacrolimus in infants with atopic dermatitis after repeated application of tacrolimus ointment. Efficacy of tacrolimus ointment, evaluated by examination of treated areas, will also be measured.

Detailed description: This is a multi-centre, double-blind, randomised phase II pharmacokinetic study in infants (3 - 24 months old) suffering from atopic dermatitis and requiring treatment with mid potency topical steroids. Patients will primarily be stratified into three groups according to percentage body surface area to be treated and subsequently randomised into treatment groups of once a day (UID) or twice a day (BID) tacrolimus ointment (0.03%) regimens. There will ultimately be a total of six groups. The study will be conducted on an out-patient basis, with each patient's parent/legal representative administering the ointment at home. However all medications on days 1 and 14 will be applied in the clinic by the Investigator or his/her designee, as will the morning application on day 4. The ointment application period will be two weeks with a follow-up period of four days. All patients enrolled into the study, who applied at least one dose of study medication and who benefited from treatment will be given the opportunity to enter a long-term study to follow (FG-506-06-33).

The patient will be entered into one of the following three groups:

Stratification Group I Application area of 5 - 20% Stratification Group II Application area of \> 20 - 40% Stratification Group III Application area of \> 40%

Within these groups the patients will be randomised to either UID or BID.

Eligibility criteria: Inclusion Criteria:

* Patient is between 3 and 24 months old on Day 1.
* The patient has atopic dermatitis requiring treatment with mid potent topical steroids.
* Patient's disease involves a percentage area to be treated greater than or equal to 5% of the total body surface area

Exclusion Criteria:

* Patient has clinically infected atopic dermatitis.
* Patient has a history of more than two courses of systemic corticosteroid treatment

Primary outcomes:
measure: Estimate the systemic exposure to tacrolimus after first and repeated application of 0.03% tacrolimus ointment in paediatric patients with atopic dermatitis stratified by application area and randomised to once a day (UID) or twice a day (BID) treatment.
timeFrame: Day 1 and 14
Secondary outcomes:
measure: Efficacy of tacrolimus ointment, evaluated by examination of treated areas.
timeFrame: Day 4, 14 and 18
Other outcomes:
Locations:
city: Halifax
country: Canada
city: Vancouver
country: Canada
city: Waterloo
country: Canada
city: Helsinki
country: Finland
city: Drogheda
country: Ireland
city: Dublin
country: Ireland
city: Riga
country: Latvia
city: London
country: United Kingdom
Study officials:
affiliation: Astellas Pharma GmbH
name: Central Contact
role: STUDY_CHAIR
References: